News | June 27, 2007

Study Shows CAD for Breast MRI Improves Standardization, Analysis of Studies

June 28, 2007 - Confirma, developer of CADstream and market leader in computer-aided detection (CAD) for breast MRI, today announced research will be published in the July issue of the journal Radiology indicating that CAD for breast MRI may improve standardization and the analysis of benign and malignant lesions.
Teresa Williams, M.D., and colleagues at the Seattle Cancer Care Alliance and the University of Washington Medical Center did a retrospective examination of 154 breast lesions deemed suspicious by radiologists that were only visible on MRI and that had been biopsied under MRI guidance (‘Breast MR Imaging: Computer Aided Evaluation (CAE) Program for Discriminating Benign and Malignant Lesions’). They compared the findings and recommendations made by radiologists at the time to the findings obtained using CAD for breast MRI to evaluate studies.
The lesions in the study had been identified and biopsied during 2001-2004 from a study population of 125 women, age 27-86. The studies were processed using CADstream, version 3.0. CAD was used to analyze the breast tissue and mark areas where the MRI data curves were characteristic of abnormal lesions. Analysis of the tissue enhancement data as displayed in the CAD-processed images identified 38 of the 41 malignant lesions examined by radiologists using the software, according to researchers. Using the standardized CAD protocols and enhancement profiles, the radiologists noticed a reduction in their false positive rate. Dr. Williams was a medical resident in radiology at the Seattle Cancer Care Alliance (SCCA) when the research was done. She is now a fellow in pediatric radiology at Children’s Hospital and Regional Medical Center in Seattle.
“There are challenges associated with breast MRI and one is the time it takes to process and evaluate the many images acquired,” said Constance Lehman, M.D., corresponding author and director of radiology at the SCCA. “Computer software programs such as the one evaluated in our study can assist us in interpreting breast MRI scans more easily. Our study suggests that the information provided may improve our ability to distinguish between benign and malignant lesions.”
For more information: www.confirma.com

Related Content

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...